Conv. Plasma
Nigella Sativa

All aspirin studies
Meta analysis
study COVID-19 treatment researchAspirinAspirin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 1% Improvement Relative Risk Case 12% Aspirin for COVID-19  Oh et al.  Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? Retrospective study in South Korea Fewer cases with aspirin (p=0.041) Oh et al., Yonsei Medical J., June 2021 Favors aspirin Favors control

Incidence and Mortality Associated with Cardiovascular Medication among Hypertensive COVID-19 Patients in South Korea

Oh et al., Yonsei Medical Journal, doi:10.3349/ymj.2021.62.7.577
Jun 2021  
  Source   PDF   All   Meta
Aspirin for COVID-19
19th treatment shown to reduce risk in March 2021
*, now known with p = 0.00014 from 72 studies, recognized in 2 countries.
Lower risk for mortality and progression.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Retrospective database analysis of 328,374 adults in South Korea, showing lower risk of COVID-19 cases with aspirin use, but no difference in mortality for COVID-19 patients.
risk of death, 1.0% lower, OR 0.99, p = 0.95, adjusted per study, multivariable, RR approximated with OR.
risk of case, 12.0% lower, RR 0.88, p = 0.04, adjusted per study, odds ratio converted to relative risk, multivariable, control prevalance approximated with overall prevalence.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Oh et al., 17 Jun 2021, retrospective, database analysis, South Korea, peer-reviewed, 4 authors.
This PaperAspirinAll
Incidence and Mortality Associated with Cardiovascular Medication among Hypertensive COVID-19 Patients in South Korea
Tak Kyu Oh, Hyoung-Won Cho, Jung-Won Suh, MD In-Ae Song
Yonsei Medical Journal, doi:10.3349/ymj.2021.62.7.577
Purpose: We aimed to investigate whether the use of cardiovascular drugs in coronavirus disease 2019 (COVID-19) patients with hypertension as a comorbidity has a significant effect on the incidence and associated mortality rate of COVID-19. Materials and Methods: Data covering the period between January 1, 2020 and June 4, 2020 were extracted from The National Health Insurance Service-COVID-19 (NHIS-COVID-19) database in South Korea and analyzed as a population-based cohort study. Results: A total of 101657 hypertensive adults aged 20 years or older were included for final analysis. Among them, 1889 patients (1.9%) were diagnosed with COVID-19 between January 1, 2020 and June 4, 2020, and hospital mortality occurred in 193 patients (10.2%). In a multivariable model, the use of beta-blockers was associated with an 18% lower incidence of COVID-19 [odds ratio (OR): 0.82, 95% confidence interval (CI): 0.69-0.98; p=0.029]. Among 1889 hypertensive patients diagnosed with COVID-19, the use of a calcium channel blocker (CCB) was associated with a 42% lower hospital mortality rate (OR: 0.58, 95% CI: 0.38-0.89; p=0.012). The use of other cardiovascular drugs was not associated with the incidence of COVID-19 or hospital mortality rate among COVID-19 patients. Similar results were observed in all 328374 adults in the NHIS-COVID-19 database, irrespective of the presence of hypertension. Conclusion: In South Korea, beta-blockers exhibited potential benefits in lowering the incidence of COVID-19 among hypertensive patients. Furthermore, CCBs may lower the hospital mortality rate among hypertensive COVID-19 patients. These findings were also applied to the general adult population, regardless of hypertension.
AUTHOR CONTRIBUTIONS Conceptualization: Tak Kyu Oh and In-Ae Song. Data curation: Hyoung-Won Cho and Jung-Won Suh. Formal analysis: Tak Kyu Oh. Investigation: Hyoung-Won Cho and Tak Kyu Oh. Methodology: Tak Kyu Oh and In-Ae Song. Supervision:In-Ae Song. Validation: Tak Kyu Oh and In-Ae Song. Visualization: Hyoung-Won Cho and Jung-Won Suh. Writing-original draft: Tak Kyu Oh. Writing-review & editing: Jung-Won Suh and In-Ae Song. Approval of final manuscript: all authors.
Alegbeleye, Akpoveso, Alegbeleye, Mohammed, Zubero, The novel aspirin as breakthrough drug for COV-ID-19: a narrative review, Iberoam J
Baigent, Blackwell, Collins, Emberson, Godwin, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Lancet
Bedford, Enria, Giesecke, Heymann, Ihekweazu et al., COVID-19: towards controlling of a pandemic, Lancet
Bianconi, Violi, Fallarino, Pignatelli, Sahebkar et al., Is acetylsalicylic acid a safe and potentially useful choice for adult patients with COVID-19?, Drugs
Chen, Wu, Chen, Yang, Chen, Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study, BMJ
Dagan, Barda, Kepten, Miron, Perchik et al., BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting, N Engl J Med
Devaux, Rolain, Raoult, ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome, J Microbiol Immunol Infect
Drager, Pio-Abreu, Lopes, Bortolotto, Is hypertension a real risk factor for poor prognosis in the COVID-19 pandemic?, Curr Hypertens Rep
Fontanet, Cauchemez, COVID-19 herd immunity: where are we?, Nat Rev Immunol
Gao, Cai, Zhang, Zhou, Zhang et al., Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study, Eur Heart J
Giannis, Ziogas, Gianni, Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past, J Clin Virol
Knoll, Wonodi, Oxford-AstraZeneca COVID-19 vaccine efficacy, Lancet
Kreutz, Algharably, Azizi, Dobrowolski, Guzik et al., Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19, Cardiovasc Res
Kuster, Pfister, Burkard, Zhou, Twerenbold et al., SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?, Eur Heart J
Lai, Millet, Daniel, Freed, Whittaker, The SARS-CoV fusion peptide forms an extended bipartite fusion platform that perturbs membrane order in a calcium-dependent manner, J Mol Biol
Liu, Huang, Xu, Yang, Qin et al., Anti-hypertensive angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients, medRxiv, doi:10.1101/2020.03.20.20039586
Mehta, Mcauley, Brown, Sanchez, Tattersall et al., COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet
Natesan, SARS-CoV-2 host cell entry might involve beta adrenergic receptors, OSF Preprints, doi:10.31219/
Noveanu, Breidthardt, Reichlin, Gayat, Potocki et al., Effect of oral β-blocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study, Crit Care
Rezel-Potts, Douiri, Chowienczyk, Gulliford, Antihypertensive medications and COVID-19 diagnosis and mortality: population-based case-control analysis in the United Kingdom, Br J Clin Pharmacol, doi:Availableat:10.1111/bcp.14873
Sardu, Maggi, Messina, Iuliano, Sardu et al., Could anti-hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID-19 infection? Data from centers of Southern Italy, J Am Heart Assoc
Schiffrin, Flack, Ito, Muntner, Webb, Hypertension and COVID-19, Am J Hypertens
South, Diz, Chappell, COVID-19, ACE2, and the cardiovascular consequences, Am J Physiol Heart Circ Physiol
Straus, Bidon, Tang, Whittaker, Daniel, FDA approved calcium channel blockers inhibit SARS-CoV-2 infectivity in epithelial lung cells, bioRxiv, doi:10.1101/2020.07.21.214577
Tan, Harazim, Tang, Mclean, Nalos, The association between premorbid beta blocker exposure and mortality in sepsis-a systematic review, Crit Care
Vasanthakumar, Can beta-adrenergic blockers be used in the treatment of COVID-19?, Med Hypotheses
Von Elm, Altman, Egger, Pocock, Gøtzsche et al., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies, Int J Surg
White, Anderson, Outcomes in patients with COVID-19 infection taking ACEI/ARB, Curr Cardiol Rep
Yang, Tan, Zhou, Yang, Peng et al., Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study, Hypertension
Zhang, Sun, Zeng, Wang, Jiang et al., Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension, Cell Discov
Zhang, Zhu, Cai, Lei, Qin et al., Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19, Circ Res
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop